Joshua Schimmer
Stock Analyst at Cantor Fitzgerald
(1.19)
# 3,414
Out of 4,712 analysts
27
Total ratings
50%
Success rate
-12%
Average return
Main Sectors:
Stocks Rated by Joshua Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio | Reiterates: Overweight | $50 | $2.36 | +2,018.64% | 4 | Apr 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Reiterates: Overweight | $50 | $41.73 | +19.82% | 2 | Nov 15, 2023 | |
| OTIS Otis Worldwide | Maintains: Equal-Weight | $91 → $92 | $93.51 | -1.61% | 4 | Jul 27, 2023 | |
| RNA Avidity Biosciences | Downgrades: In-Line | $20 | $31.64 | -36.79% | 1 | Mar 31, 2023 | |
| BNOX Bionomics | Upgrades: Outperform | $6 | $0.25 | +2,270.60% | 2 | Mar 10, 2023 | |
| NBIX Neurocrine Biosciences | Upgrades: Outperform | $130 | $136.99 | -5.10% | 1 | Mar 3, 2023 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $80 → $50 | $20.78 | +140.62% | 1 | Feb 28, 2023 | |
| TGTX TG Therapeutics | Maintains: Outperform | $16 → $25 | $32.26 | -22.50% | 3 | Jan 24, 2023 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $65 → $75 | $11.43 | +556.17% | 1 | Sep 30, 2022 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | $90 → $100 | $66.27 | +50.90% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $715.13 | - | 2 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $1,720 → $2,000 | $7.66 | +26,009.66% | 2 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $69.84 | +21.71% | 3 | May 31, 2018 |
Cabaletta Bio
Apr 5, 2024
Reiterates: Overweight
Price Target: $50
Current: $2.36
Upside: +2,018.64%
Mirum Pharmaceuticals
Nov 15, 2023
Reiterates: Overweight
Price Target: $50
Current: $41.73
Upside: +19.82%
Otis Worldwide
Jul 27, 2023
Maintains: Equal-Weight
Price Target: $91 → $92
Current: $93.51
Upside: -1.61%
Avidity Biosciences
Mar 31, 2023
Downgrades: In-Line
Price Target: $20
Current: $31.64
Upside: -36.79%
Bionomics
Mar 10, 2023
Upgrades: Outperform
Price Target: $6
Current: $0.25
Upside: +2,270.60%
Neurocrine Biosciences
Mar 3, 2023
Upgrades: Outperform
Price Target: $130
Current: $136.99
Upside: -5.10%
Denali Therapeutics
Feb 28, 2023
Maintains: Outperform
Price Target: $80 → $50
Current: $20.78
Upside: +140.62%
TG Therapeutics
Jan 24, 2023
Maintains: Outperform
Price Target: $16 → $25
Current: $32.26
Upside: -22.50%
Rocket Pharmaceuticals
Sep 30, 2022
Maintains: Outperform
Price Target: $65 → $75
Current: $11.43
Upside: +556.17%
BioMarin Pharmaceutical
Mar 1, 2021
Upgrades: Outperform
Price Target: $90 → $100
Current: $66.27
Upside: +50.90%
Feb 25, 2020
Upgrades: Outperform
Price Target: n/a
Current: $715.13
Upside: -
Feb 3, 2020
Upgrades: Outperform
Price Target: $1,720 → $2,000
Current: $7.66
Upside: +26,009.66%
May 31, 2018
Assumes: Overweight
Price Target: $85
Current: $69.84
Upside: +21.71%